{
  "paper_id": "PMC3222247",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3222247/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "The current classification of myeloid neoplasm. CNL: chronic neutrophilic leukemia, CMML: chronic myelomonocytic leukemia, JCMML: juvenile myelomonocytic leukemia, aCML: atypical chronic myelogenous leukemia.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d995d4f60393/hr-2009-1-e10-g001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d995d4f60393/hr-2009-1-e10-g001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d995d4f60393/hr-2009-1-e10-g001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d995d4f60393/hr-2009-1-e10-g001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d995d4f60393/hr-2009-1-e10-g001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC3222247/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d995d4f60393/hr-2009-1-e10-g001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "The rate of progression of chronic myeloid neoplasms to leukemic phase. Pre: pre-fibrotic stage of PMF and unexplained thrombotic events prior to the development of MPN.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d5550afa9832/hr-2009-1-e10-g002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d5550afa9832/hr-2009-1-e10-g002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d5550afa9832/hr-2009-1-e10-g002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d5550afa9832/hr-2009-1-e10-g002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d5550afa9832/hr-2009-1-e10-g002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC3222247/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/d5550afa9832/hr-2009-1-e10-g002.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "The structure of Janus kinases",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ba74e1dfa5b4/hr-2009-1-e10-g003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ba74e1dfa5b4/hr-2009-1-e10-g003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ba74e1dfa5b4/hr-2009-1-e10-g003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ba74e1dfa5b4/hr-2009-1-e10-g003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ba74e1dfa5b4/hr-2009-1-e10-g003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC3222247/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ba74e1dfa5b4/hr-2009-1-e10-g003.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "Steps of JAK-STAT pathway.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/2cc6e3c5a46b/hr-2009-1-e10-g004.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/2cc6e3c5a46b/hr-2009-1-e10-g004.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/2cc6e3c5a46b/hr-2009-1-e10-g004.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/2cc6e3c5a46b/hr-2009-1-e10-g004.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/2cc6e3c5a46b/hr-2009-1-e10-g004.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC3222247/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/2cc6e3c5a46b/hr-2009-1-e10-g004.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Figure 5.",
      "caption": "Factors that might determine the phenotype of JAK2 mutation positive disorders.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/98f71980ffe4/hr-2009-1-e10-g005.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/98f71980ffe4/hr-2009-1-e10-g005.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/98f71980ffe4/hr-2009-1-e10-g005.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/98f71980ffe4/hr-2009-1-e10-g005.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/98f71980ffe4/hr-2009-1-e10-g005.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC3222247/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/98f71980ffe4/hr-2009-1-e10-g005.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Figure 6.",
      "caption": "JAK2 mutation burden during progression of MPNs. AL: acute leukemia, ET: essential thrombocythemia, MF: myelofibrosis, PMF: primary myelofibrosis, PV: poly-cythemia vera.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ab903917f7bd/hr-2009-1-e10-g006.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ab903917f7bd/hr-2009-1-e10-g006.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ab903917f7bd/hr-2009-1-e10-g006.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ab903917f7bd/hr-2009-1-e10-g006.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F6",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ab903917f7bd/hr-2009-1-e10-g006.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC3222247/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f69/3222247/ab903917f7bd/hr-2009-1-e10-g006.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The diagnosis and classification of these disorders are based on peripheral blood counts, blast percentage, type of myelosis, presence of significant dysplasia, extent of fibrosis, clinical features, biochemistry and most importantly genetics.2–4\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe structure of Janus kinasesUpon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The diagnosis and classification of these disorders are based on peripheral blood counts, blast percentage, type of myelosis, presence of significant dysplasia, extent of fibrosis, clinical features, biochemistry and most importantly genetics.2–4\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe structure of Janus kinasesUpon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The diagnosis and classification of these disorders are based on peripheral blood counts, blast percentage, type of myelosis, presence of significant dysplasia, extent of fibrosis, clinical features, biochemistry and most importantly genetics.2–4\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe structure of Janus kinasesUpon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The diagnosis and classification of these disorders are based on peripheral blood counts, blast percentage, type of myelosis, presence of significant dysplasia, extent of fibrosis, clinical features, biochemistry and most importantly genetics.2–4\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe structure of Janus kinasesUpon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The diagnosis and classification of these disorders are based on peripheral blood counts, blast percentage, type of myelosis, presence of significant dysplasia, extent of fibrosis, clinical features, biochemistry and most importantly genetics.2–4\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe structure of Janus kinasesUpon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The diagnosis and classification of these disorders are based on peripheral blood counts, blast percentage, type of myelosis, presence of significant dysplasia, extent of fibrosis, clinical features, biochemistry and most importantly genetics.2–4\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe structure of Janus kinasesUpon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The diagnosis and classification of these disorders are based on peripheral blood counts, blast percentage, type of myelosis, presence of significant dysplasia, extent of fibrosis, clinical features, biochemistry and most importantly genetics.2–4\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe structure of Janus kinasesUpon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The diagnosis and classification of these disorders are based on peripheral blood counts, blast percentage, type of myelosis, presence of significant dysplasia, extent of fibrosis, clinical features, biochemistry and most importantly genetics.2–4\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe structure of Janus kinasesUpon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "The diagnosis and classification of these disorders are based on peripheral blood counts, blast percentage, type of myelosis, presence of significant dysplasia, extent of fibrosis, clinical features, biochemistry and most importantly genetics.2–4\nFigure 1.",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5\nFigure 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Chronic leukemia can be sub-divided into BCR/ABL positive or negative, those BCR/ABL positive will be labeled as CML regardless of their clinico-pathological features unless it is presenting as acute leukemia, while those BCR/ABL negative will be divided further into classical MPNs, non-classical MPNs with or without dysplasia, and myelodysplastic syndrome (MDS) (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "One of the interesting things regarding the clinical features of myeloid neoplasms is their tendency to transform to acute leukemia; the classical MPNs, beside their pre-leukemic behavior, progress and regress to each other (Figure 2).3–5.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Open in a new tab\nThe structure of Janus kinasesUpon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "One of these (JH1) is an activating domain while the other (JH2) seems to exert an inhibitory effect (Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Upon ligand binding to its specific receptor, JAK protein will be activated and it will then phosphorylate the downstream signaling molecules like STATs, which will be actively transported to the nucleus where it will activate transcription factors (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Many factors possibly play a role (Figure 5).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44\nFigure 6.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "The overwhelming blasts will, therefore, reduce the allele mutation burden which might be considered a sign of evolution if it is not related to chemical cytoreductive therapy (Figure 6).41,44.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 6,
    "claims_count": 71,
    "images_downloaded": 6,
    "tables_filtered": 63
  }
}